SRZN News and Press, Surrozen Inc. From 05/10/23

Enrollment ongoing in SZN-043 Phase 1a clinical trial in people with chronic liver disease and in healthy volunteers with safety data expected by the end of 2023 Enrollment ongoing in SZN-1326 Phase 1a clinical trial in healthy volunteers with safety data expected by the end of 2023 ...

SOUTH SAN FRANCISCO, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today announced that Er...

2023-03-25 10:02:10 ET Surrozen, Inc. (SRZN) Q4 2022 Earnings Conference Call March 22, 2023, 16:30 ET Company Participants Craig Parker - CEO, President & Director Charles Williams - CFO Conference Call Participants Dae Gon Ha - Stifel, Nicolaus &...

2023-03-22 17:27:31 ET Surrozen press release ( NASDAQ: SRZN ): FY GAAP EPS of -$1.04. Revenue of $12.5M. For further details see: Surrozen GAAP EPS of -$1.04, revenue of $12.5M

Enrolled first patient in SZN-043 Ph 1a clinical trial in chronic liver disease with data expected by the end of 2023 Expect to begin SZN-043 Ph1b clinical trial in severe alcoholic hepatitis in 2024 with proof-of-concept data expected in the second half of 2024 Expect to reinit...

SOUTH SAN FRANCISCO, Calif., March 20, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), today announced that it will report fourth quarter and full year 2022 financial results and provide a corporate and pipeline progress report on ...

Diversifying Your Penny Stocks Portfolio, 3 Tips Diversifying your penny stock portfolio is a key strategy for reducing risk and maximizing returns. By spreading your investments across a range of penny stocks , you can reduce the impact of any individual stock’s performance on you...

Why Trade Penny Stocks? Penny stocks are shares of small companies that trade for less than $5 per share. They are seen as an attractive investment option for smaller investors or those with limited capital. That’s due to their affordability and the potential for high returns. Here are...

Summary Baker Brothers’ 13F portfolio value decreased from $17.63B to $15.27B this quarter. Rhythm Pharma and Akero Therapeutics were increased while decreasing argenx SE and Horizon Therapeutics. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they a...

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, will present on Jan...